Allergan and Gedeon Richter ready to knock on FDA's door after a positive PhIII for cariprazine in bipolar depression
Cariprazine is now 1 and 1 in Phase III bipolar depression studies. And the researchers involved say that should be good enough for a green light from regulators.
After racking up a late-stage failure last year for bipolar patients, researchers for Allergan $AGN and its partners at Gedeon Richter remained doggedly determined to stick it out. And in their second Phase III study the partners say they came up with solidly positive results — though the actual numbers were held back from the release.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
